OncoMatch/Clinical Trials/NCT07056790
Research on the Application of 68Ga-PSMA-CYC PET Imaging in the Diagnosis, Staging, and Restaging of Prostate Cancer
Is NCT07056790 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including 68Ga-PSMA-CYC and CYC for prostate ca.
Treatment: 68Ga-PSMA-CYC · CYC — 68Ga-PSMA-CYC is a novel radiotracer targeting PSMA. In this study, we investigated the safety, biodistribution, radiation dosimetry of 68Ga-PSMA-CYC PET/CT in patients with prostate cancer, and performed a head-to-head comparison with 68Ga-PSMA-617 and 68Ga-PSMA-11 to evaluate its diagnostic performance.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Biomarker criteria
Required: FOLH1 imaging
68Ga-PSMA-CYC PET Imaging
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07056790 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require FOLH1?
Yes, FOLH1 imaging is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify